What is TheraVectys?
TheraVectys is a specialized biotechnology firm focused on the application of lentiviral vectors to address critical challenges in oncology and infectious diseases. The company operates at the intersection of immunology and genetic engineering, aiming to provide curative solutions through personalized vaccination strategies. With a robust portfolio that includes candidates for hepatitis B, liver cancer, and COVID-19, TheraVectys has established a collaborative ecosystem involving academic institutions like the Institut Pasteur and industrial partners across Europe, North America, and China. Its market position is defined by its commitment to transitioning from pre-clinical proof-of-concept studies to high-impact Phase I/IIa clinical trials, positioning the firm as a potential leader in the next generation of immunotherapy.
How much funding has TheraVectys raised?
TheraVectys has raised a total of $51.4M across 4 funding rounds:
Private Equity
$9.4M
Unspecified
$19.9M
Grant
$2.1M
Unspecified
$20M
Private Equity (2012): $9.4M, investors not publicly disclosed
Unspecified (2013): $19.9M led by FGP Capital
Grant (2015): $2.1M supported by Bpifrance
Unspecified (2021): $20M, investors not publicly disclosed
Key Investors in TheraVectys
Bpifrance
A French public investment bank that provides credit, guarantees, and equity to support innovation and international growth for companies at various stages of development.
FGP Capital
A Swiss investment firm specializing in late-stage healthcare and technology opportunities, with a particular focus on financing clinical research and university spin-offs.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for TheraVectys?
With the recent capital injection, TheraVectys is poised to scale its clinical development operations significantly. The strategic roadmap includes the advancement of its Lenti-Covid nasal vaccine and the initiation of proprietary Phase I/IIa clinical trials targeting oncology. As the company moves deeper into the clinical phase, the focus will shift toward demonstrating platform efficacy and securing regulatory milestones. The ongoing collaboration with international partners, particularly in the Chinese market, suggests a deliberate strategy to capture global market share in the immunotherapy space. Investors and stakeholders will be closely monitoring the readout of these upcoming trials, which are expected to serve as a critical validation of the company's lentiviral technology and its long-term commercial viability.
See full TheraVectys company page
